[Improvement of host-immunity by adjuvant therapy with juzen-taiho-to for patients with brain tumors].
T cell subset, natural killer (NK) cell activity and tumor necrosis factor alpha (TNF-alpha) productivity of lymphocytes in the peripheral blood were investigated in order to study host-immunity before and after administration of Juzentaiho-to (TJ-48) with or without Interferon-beta (INF-beta) for 29 patients with brain tumors (15 cases of gliomas and 14 cases of non-glial tumors). "A" group was given TJ-48 (7.5 g/day, p.o.) with INF-beta 300 million IU/1-2 weeks after initial treatment, and "B" group was treated by only TJ-48. % values of helper T cells (CD4+, CD45RA-), cytotoxic T cells (CD8+, 11b-), suppressor T cells (CD8+ +. 11b+) and NK activity were calculated with two color flowcytometry before and at 1 month, 2 months and 3 months after the administration of TJ-48. TNF-alpha productivity of lymphocytes was examined by the ELISA method at the same time. Suppressor T cells decreased significantly after 2 months following administration of JT-48 in 16 of 17 cases in both A and B group. After administration of TJ-48, helper T cells tended to increase slightly, but cytotoxic T cells and NK activity did not change. TNF-alpha productivity was measured in 8 cases of gliomas and increased to levels higher than they were before administration of TJ-48 in all of the cases which were examined more than 2 months after treatment. Adjuvant therapy with TJ-48 in both A and B group improved the host-immunity of the patients with brain tumors. It was concluded that it was useful as an assistant treatment for brain tumors.